科美诊断(688468) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥100,933,657.63, representing a decrease of 16.50% compared to the same period last year[4] - The net profit attributable to shareholders was ¥34,836,760.84, down by 10.92% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥30,632,434.37, a decrease of 12.54% compared to the previous year[4] - The basic earnings per share for the period was ¥0.09, a decrease of 10.00% compared to the same period last year[4] - The weighted average return on equity was 2.49%, a decrease of 0.52 percentage points[4] - The total comprehensive income for Q1 2023 was ¥34,836,760.84, compared to ¥39,107,317.86 in Q1 2022[22] - The net profit for Q1 2023 was ¥34,836,760.84, a decline of 10.0% from ¥39,107,317.86 in Q1 2022[21] - The net profit for Q1 2023 was -3,612,514.55 RMB, an improvement from -6,052,137.88 RMB in Q1 2022, indicating a reduction in losses by approximately 40%[30] - Total comprehensive income for Q1 2023 was -3,612,514.55 RMB, compared to -6,052,137.88 RMB in Q1 2022, reflecting a significant improvement in overall financial performance[30] Cash Flow - The net cash flow from operating activities was ¥18,271,622.63, reflecting a significant decline of 68.99% due to reduced sales collections and increased tax and procurement expenses[6] - Cash inflow from operating activities in Q1 2023 was ¥123,823,308.66, down from ¥143,862,718.38 in Q1 2022[22] - The net cash flow from operating activities was CNY 18,271,622.63, down 69.0% from CNY 58,921,042.84 in the previous year[23] - The total cash outflow from operating activities was 33,286,323.62 RMB, compared to 28,125,115.24 RMB in Q1 2022, marking an increase of approximately 18%[34] - The company incurred a tax expense of -2,231,800.27 RMB in Q1 2023, compared to -1,537,773.85 RMB in Q1 2022, reflecting an increase in tax liabilities[30] - The company's cash flow from financing activities resulted in a net outflow of -2,217,334.84 RMB, compared to -12,353,360.41 RMB in Q1 2022, indicating a significant reduction in financing costs[34] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,577,016,660.57, a decrease of 0.89% from the end of the previous year[5] - The total assets as of March 31, 2023, amounted to CNY 1,116,991,175.71, a decrease from CNY 1,131,638,710.08 at the end of 2022[26] - Total liabilities as of Q1 2023 were ¥161,604,646.97, a decrease from ¥210,591,173.95 in the previous period[17] - The company's total liabilities as of March 31, 2023, were CNY 16,347,849.35, down from CNY 27,382,869.17 at the end of 2022[27] Research and Development - Research and development expenses totaled ¥21,574,900.89, which is an increase of 16.60% year-on-year, accounting for 21.38% of operating revenue, up by 6.07 percentage points[4] - The company reported a decrease in research and development expenses to ¥17,088,512.72 in Q1 2023 from ¥18,502,792.33 in Q1 2022[19] - Research and development expenses for Q1 2023 were CNY 10,909,511.00, slightly up from CNY 10,877,795.20 in Q1 2022[29] - The company has 15 products in the research pipeline, with 4 entering clinical stages and 1 obtaining domestic Class III medical device registration during the reporting period[11] - The company secured 8 domestic invention patents during the reporting period, indicating ongoing innovation efforts[12] Inventory and Current Assets - The company reported a total current assets of CNY 1,137,751,671.82 as of March 31, 2023, a decrease from CNY 1,165,252,004.65 at the end of 2022, reflecting a decline of approximately 2.5%[14] - The cash and cash equivalents decreased to CNY 247,051,012.53 from CNY 342,139,661.72, representing a decline of about 27.8%[14] - The accounts receivable decreased to CNY 31,492,953.67 from CNY 34,062,994.04, a decline of about 8.3%[14] - The company’s inventory increased to CNY 113,377,180.33 from CNY 112,560,499.21, reflecting a slight increase of about 0.7%[15] - The company’s inventory increased slightly to CNY 31,153,709.50 from CNY 30,966,985.10 at the end of 2022[26] Investment Activities - Investment activities resulted in a net cash outflow of CNY 120,379,638.70, compared to a smaller outflow of CNY 38,824,910.50 in the previous year[23] - The cash flow from investing activities showed a net outflow of -126,392,250.78 RMB, compared to -152,610,099.14 RMB in Q1 2022, indicating a reduction in cash outflow by approximately 17%[34]